Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) CFO Sells $340,893.00 in Stock

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) CFO Dominic Piscitelli sold 32,466 shares of the company's stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $10.50, for a total transaction of $340,893.00. Following the completion of the sale, the chief financial officer now directly owns 68,317 shares of the company's stock, valued at $717,328.50. The trade was a 32.21% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Dominic Piscitelli also recently made the following trade(s):

• On Monday, June 23rd, Dominic Piscitelli sold 1,034 shares of Oric Pharmaceuticals stock. The shares were sold at an average price of $10.00, for a total transaction of $10,340.00.
• On Thursday, June 12th, Dominic Piscitelli sold 300 shares of Oric Pharmaceuticals stock. The shares were sold at an average price of $10.00, for a total transaction of $3,000.00.
• On Wednesday, June 11th, Dominic Piscitelli sold 2,976 shares of Oric Pharmaceuticals stock. The shares were sold at an average price of $10.01, for a total transaction of $29,789.76.
• On Tuesday, June 10th, Dominic Piscitelli sold 324 shares of Oric Pharmaceuticals stock. The shares were sold at an average price of $10.00, for a total transaction of $3,240.00.
• On Monday, June 9th, Dominic Piscitelli sold 300 shares of Oric Pharmaceuticals stock. The shares were sold at an average price of $10.00, for a total transaction of $3,000.00.
• On Friday, June 6th, Dominic Piscitelli sold 2,600 shares of Oric Pharmaceuticals stock. The shares were sold at an average price of $10.01, for a total transaction of $26,026.00.

Oric Pharmaceuticals Trading Up 4.9%

Shares of NASDAQ:ORIC traded up $0.49 during trading on Tuesday, reaching $10.49. 1,161,709 shares of the company traded hands, compared to its average volume of 787,784. The firm has a fifty day simple moving average of $6.82 and a 200 day simple moving average of $7.68. Oric Pharmaceuticals, Inc. has a 1-year low of $3.90 and a 1-year high of $14.67.

Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last issued its earnings results on Monday, May 5th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.51) by $0.09. On average, equities analysts expect that Oric Pharmaceuticals, Inc. will post -2.17 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on ORIC shares. Wedbush restated an "outperform" rating and set a $20.00 target price on shares of Oric Pharmaceuticals in a report on Monday. Oppenheimer reduced their target price on shares of Oric Pharmaceuticals from $15.00 to $12.00 and set an "outperform" rating for the company in a report on Tuesday, May 6th. Cantor Fitzgerald restated an "overweight" rating on shares of Oric Pharmaceuticals in a report on Tuesday, May 6th. HC Wainwright restated a "buy" rating and set a $21.00 target price on shares of Oric Pharmaceuticals in a report on Monday, May 5th. Finally, Guggenheim restated a "buy" rating on shares of Oric Pharmaceuticals in a report on Wednesday, February 26th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $19.17.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of ORIC. Boxer Capital Management LLC bought a new position in shares of Oric Pharmaceuticals during the 4th quarter valued at $13,982,000. MPM Bioimpact LLC bought a new position in shares of Oric Pharmaceuticals during the 1st quarter valued at $7,809,000. Vivo Capital LLC raised its holdings in shares of Oric Pharmaceuticals by 62.8% during the 1st quarter. Vivo Capital LLC now owns 2,080,450 shares of the company's stock valued at $11,609,000 after purchasing an additional 802,632 shares in the last quarter. Schonfeld Strategic Advisors LLC bought a new position in shares of Oric Pharmaceuticals during the 4th quarter valued at $5,845,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Oric Pharmaceuticals by 1,331.1% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 509,179 shares of the company's stock valued at $2,841,000 after purchasing an additional 473,600 shares in the last quarter. Institutional investors own 95.05% of the company's stock.

Oric Pharmaceuticals Company Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.